Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Increased by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 7.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,018 shares of the medical research company's stock after purchasing an additional 3,268 shares during the period. Janus Henderson Group PLC owned about 0.09% of Charles River Laboratories International worth $9,064,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Tortoise Investment Management LLC lifted its position in shares of Charles River Laboratories International by 77.0% during the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock worth $27,000 after purchasing an additional 57 shares in the last quarter. Wolff Wiese Magana LLC acquired a new position in shares of Charles River Laboratories International during the third quarter worth $32,000. Assetmark Inc. raised its holdings in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after acquiring an additional 173 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock valued at $58,000 after acquiring an additional 193 shares in the last quarter. Finally, Covestor Ltd raised its holdings in Charles River Laboratories International by 40.9% in the third quarter. Covestor Ltd now owns 327 shares of the medical research company's stock valued at $65,000 after acquiring an additional 95 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

CRL traded up $9.95 on Monday, reaching $201.76. The company had a trading volume of 630,045 shares, compared to its average volume of 619,013. The company has a fifty day moving average of $194.19 and a 200-day moving average of $203.56. The company has a market capitalization of $10.32 billion, a P/E ratio of 25.25, a PEG ratio of 4.95 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a one year low of $176.48 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same quarter last year, the firm posted $2.72 EPS. The business's revenue for the quarter was down 1.6% on a year-over-year basis. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on CRL shares. StockNews.com cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Thursday, November 7th. Bank of America cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price target for the company from $250.00 to $215.00 in a report on Wednesday, October 2nd. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a "sell" rating and a $151.00 price target on the stock. Evercore ISI upped their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a report on Thursday, November 7th. Finally, UBS Group upped their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $214.38.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).